Willkie Farr & Gallagher advises PAI Partners on Zydus Lifesciences’ €256.8 million acquisition of Amplitude Surgical’s ...

Equities researchers at DA Davidson raised their FY2026 earnings per share (EPS) estimates for Amplitude in a report issued on Tuesday, March 11th. DA Davidson analyst C. Wright now forecasts that the ...

Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopaedics and ...

Amplitude (NASDAQ:AMPL – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They currently have a $16.

SAN FRANCISCO, March 07, 2025--(BUSINESS WIRE)--Amplitude (Nasdaq: AMPL), the leading digital analytics platform, will host its previously announced investor day on Monday, March 10, 2025 beginning at ...

Brokerage firms remain divided on Zydus Lifesciences as the company announced to acquire France-based Amplitude Surgical for ...

Amplitude's enterprise sales strategy is driving significant ARR growth. See why I reiterate my buy rating on AMPL stock.

Zydus Lifesciences on Tuesday said it has entered into exclusive negotiations to acquire a majority stake in France-based ...

India still relies largely on imported devices and implants, when it comes to MedTech. This offers us a great opportunity to ...

Needham analyst Scott Berg initiated coverage of Amplitude (AMPL) with a Buy rating and $16 price target The firm views Amplitude shares to be ...

Medical Technology includes medical devices and related scientific infrastructure that directly contribute to the development ...

Regulatory News: Zydus Lifesciences Limited2 ("Zydus"), a global innovation-driven lifesciences company has entered into exclusive negotiations to purchase3 from PAI Partners and Amplitude Surgical’s ...